Mycophenolate mofetil as adjuvant in pemphigus vulgaris.
Indian J Dermatol Venereol Leprol
;
2007 Sep-Oct; 73(5): 348-50
Artículo
en Inglés
| IMSEAR
| ID: sea-52326
ABSTRACT
Pemphigus vulgaris (PV) is a life threatening autoimmune blistering disease of skin and mucous membranes. Advent of systemic steroids has greatly reduced the mortality rate. However, steroids and adjuvant immunosuppressive therapy are nowadays frequent contributory agents of morbidity and mortality of PV. Mycophenolate mofetil (MMF) has been reported to be an effective adjuvant to systemic steroids. It helps in increasing the immunosuppressive effect and minimizing the toxicities by steroid sparing effect. However, its efficacy in refractory cases of PV is not well documented. The lowest possible dose with satisfactory therapeutic efficacy and least side effects is known. We used MMF 1 g/day and systemic steroids in 3 Indian patients with pemphigus vulgaris who were resistant to systemic steroid monotherapy or combination treatment with azathioprine. In our experience, MMF offers an effective adjuvant with minimal side-effects in the treatment of resistant PV.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Piel
/
Femenino
/
Humanos
/
Masculino
/
Prednisolona
/
Pénfigo
/
Adulto
/
Quimioterapia Combinada
/
Glucocorticoides
/
Inmunosupresores
Idioma:
Inglés
Revista:
Indian J Dermatol Venereol Leprol
Año:
2007
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS